These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 1958393)
1. Alizapride alone or alizapride-dexamethasone compared with metoclopramide-dexamethasone in patients at high risk of acute emesis after cisplatin. A randomized cross-over study. Pollera CF; Nardi M; Marolla P; Calabresi F Acta Oncol; 1991; 30(6):725-9. PubMed ID: 1958393 [TBL] [Abstract][Full Text] [Related]
2. A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin. Pollera CF; Nardi M; Marolla P; Carlini P Cancer Chemother Pharmacol; 1987; 19(4):335-8. PubMed ID: 3297376 [TBL] [Abstract][Full Text] [Related]
3. High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy. Strum SB; McDermed JE; Liponi DF J Clin Oncol; 1985 Feb; 3(2):245-51. PubMed ID: 4038511 [TBL] [Abstract][Full Text] [Related]
4. Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. Pollera CF; Nardi M; Marolla P; Pinnaró P; Terzoli E; Giannarelli D Am J Clin Oncol; 1989 Dec; 12(6):524-9. PubMed ID: 2589233 [TBL] [Abstract][Full Text] [Related]
5. Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. Bleiberg H; Gerard B; Dalesio O; Crespeigne N; Rozencweig M Cancer Chemother Pharmacol; 1988; 22(4):316-20. PubMed ID: 3048762 [TBL] [Abstract][Full Text] [Related]
6. [Phase I study of alizapride in cancer patients treated with cisplatin]. Nicaise C; Rozencweig M; Ortmans M; Frisque C; Bleiberg H Sem Hop; 1983 Sep; 59(31):2161-5. PubMed ID: 6312589 [TBL] [Abstract][Full Text] [Related]
7. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. Joss RA; Galeazzi RL; Bischoff AK; Pirovino M; Ryssel HJ; Brunner KW Clin Pharmacol Ther; 1986 Jun; 39(6):619-24. PubMed ID: 3519041 [TBL] [Abstract][Full Text] [Related]
8. Randomized open cross-over trial between metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting. Cognetti F; Pinnarò P; Carlini P; Conti EM; Cortese M; Pollera CF Eur J Cancer Clin Oncol; 1984 Feb; 20(2):183-7. PubMed ID: 6368241 [TBL] [Abstract][Full Text] [Related]
9. A prospective randomized double-blind crossover study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapy. Basurto C; Roila F; Del Favero A; Ballatori E; Minotti V; Tonato M Cancer Invest; 1988; 6(5):475-9. PubMed ID: 3063335 [TBL] [Abstract][Full Text] [Related]
10. Randomized trial for the control of acute vomiting in cisplatin-treated patients: high-dose metoclopramide with dexamethasone and lorazepam as adjuncts versus high-dose alizapride plus dexamethasone and lorazepam. Study of the incidence of delayed emesis. Moreno I; Rosell R; Abad-Esteve A; Barnadas A; Carles J; Ribelles N Oncology; 1991; 48(5):397-402. PubMed ID: 1745488 [TBL] [Abstract][Full Text] [Related]
11. Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy. Zambetti M; Bajetta E; Bidoli P; Verusio C Tumori; 1985 Dec; 71(6):609-14. PubMed ID: 4082295 [TBL] [Abstract][Full Text] [Related]
12. Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Moreno I; Rosell R; Abad A; Barnadas A; Carles J; Ribelles N; Solano V; Font A Eur J Cancer; 1992; 28A(8-9):1344-7. PubMed ID: 1515247 [TBL] [Abstract][Full Text] [Related]
14. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. Sorbe BG Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123 [TBL] [Abstract][Full Text] [Related]
15. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis. Bhatia A; Tripathi KD; Sharma M Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556 [TBL] [Abstract][Full Text] [Related]
16. [Randomized study of the antiemetic efficacy of alizapride versus alizapride + dexamethasone]. Epifani C; Scognamiglio G; Prete C; Alberio F; Gini G; Valli M G Ital Oncol; 1990; 10(4):115-9. PubMed ID: 2093079 [TBL] [Abstract][Full Text] [Related]
17. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy. Bhatia A; Tripathi KD; Sharma M Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464 [TBL] [Abstract][Full Text] [Related]
18. Improved control of cisplatin-induced emesis with a metoclopramide-dexamethasone combination. Cognetti F; Pinnaro P; Carlini P; Caporali C; Ruggeri EM; Pollera CF Cancer Chemother Pharmacol; 1984; 13(3):235-7. PubMed ID: 6541533 [TBL] [Abstract][Full Text] [Related]
19. Comparative effects of intravenously administered alizapride and prochlorperazine in cisplatin-induced emesis. Roché H; Hyman G; Nahas G; Stoopler M; Ellison R; Desjardins R Cancer Invest; 1987; 5(2):89-93. PubMed ID: 3607576 [TBL] [Abstract][Full Text] [Related]
20. [Control of the emesis induced by cisplatin in patients with head and neck neoplasms. Randomized study of metoclopramide alizapride and placebo]. Denaro A; Rossi M; Garozzo A; Matera M; Neri V G Ital Oncol; 1990; 10(1-2):29-34. PubMed ID: 2192985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]